On This Page
iVC Venture Innovation Fund
Key Statistics
Fund Size
€80M
Target Return
9.5%
Launch Year
2024
Min. Investment
€10,000
Availability
Open for public
Structure
German closed-end public AIF (GmbH & Co. geschlossene Investment KG)
Product Category
Closed-end
Domicile
Germany
GP Type
Single
Liquidity Level
Low (5+ years)
Management Fee
1.3%
Carry
10%
High Water Mark
No
ISIN
DE000A3EKRR1
Currencies
EUR
Investor Eligibility
Retail
Liquidity Options
Illiquid; no redemption rights
Highlights
Key Information Document (KID) – EU Funds
KID Risk Indicator
6 out of 7
Annual Returns (KID Scenarios)
Stressed
-100%
Moderate
6.3%
Favorable
9.5%
Average Total Cost Level (KID)
2.8%
Allocations
Geographic Focus
Investment Strategy
Industry Focus
Portfolio Composition
Information about fund
Venture Capital Funds of Funds for €10,000
iVC Venture Innovation Fund is a German retail venture-capital fund of funds: a closed-end public AIF (GmbH & Co. geschlossene Investment KG) initiated by inVenture Capital of Hamburg and Berlin and administered by HANSAINVEST as its licensed management company. The fund does not invest directly in start-ups but in 10 to 15 European venture funds with different strategies, regions and stages, giving a single ticket exposure to more than 200 start-ups in deep tech, healthcare, clean tech and digitalisation. Fund managers must have at least three fund generations and a top-quartile track record.
Key Facts
Target Funds
10–15
200+ start-ups look-through
Minimum
€10,000
+5% agio
Placement Ceiling
€80M
Raised to date not disclosed
Term
13 years
No redemptions
KID
Risk 6/7
Costs ~2.8%; moderate 6.3%
Manager of Record
HANSAINVEST
Initiator inVenture Capital
Terms and Risk
The fund can grow to €80 million and takes tickets from €10,000 plus a 5% agio, far below the €200,000 that institutional venture funds usually require. The term is 13 years and there are no redemption rights; distributions come only as the underlying funds exit. The KID places it in risk class 6 of 7 with total costs of about 2.8% a year, a moderate scenario of 6.3%, a favourable one of 9.5% and a stress scenario of total loss. Fundscouter’s record shows a 1.3% management fee and 10% carry, which could not be verified against a public prospectus.
Terms
| Structure | German closed-end Publikums-AIF; KVG HANSAINVEST; initiator inVenture Capital (Hamburg/Berlin) |
| ISIN | DE000A3EKRR1 |
| Selection | Managers with 3+ fund generations and top-quartile records; deep tech, healthcare, clean tech, digitalisation |
| Fees | Record: 1.3% management fee, 10% carry (unverified); total KID cost ~2.8% p.a. |
| Scenarios | Moderate 6.3% p.a., favourable 9.5%, stress: total loss |
Deepdive & Related Funds
Comparable Funds
MIG Fonds 18
MIG Fonds 18 is the eighteenth retail venture capital fund of the MIG programme (manager MIG Capital AG, structured by HMW Kapitalanlagen AG), a German closed-end Investment-KG taking minority stakes in 10–15 European deep-tech companies in biotech, medtech, digital health, robotics, ICT and materials. Placement ceiling €160 million; early holdings CoreMedic, ASTRA Therapeutics, NcodiN and Luffy AI. From €5,000 plus 5% agio (or €18,000 in six instalments), term to 31 December 2037, KID risk 6/7 with total costs ~5.1% a year.
MPE Direct Return 6
MPE Direct Return 6 is Munich Private Equity’s shorter-cycle fund-of-funds, now closed: a BaFin-regulated German closed-end Investment-KG that invests in private equity funds already substantially invested, so distributions can begin from 2029 with the basic term ending in 2035. Entry costs 9.9%, running costs 2.14% a year, performance fee above a 5% hurdle; KID moderate scenario 3.8% a year net, risk 6/7. No early exit.
MPE International 9
MPE International 9 is Munich Private Equity’s (formerly RWB) current retail private equity fund-of-funds: a BaFin-regulated German closed-end Investment-KG committing to lower mid-market buyout funds in North America and Europe. Over €100 million subscribed by July 2026, 39 target funds and 130+ companies already; placement runs to June 2027. From €5,000 or €50 a month; entry costs up to 17.9%, running costs 1.7–2.1% a year; term to 2040; KID moderate scenario 5.2% a year net.
Altaroc Odyssey 2024
Altaroc Odyssey 2024 is the fourth Altaroc vintage: a French FPCI (with ELTIF classes for Europe) that closed on 31 March 2025 with €355 million, committing 80% to top-tier buyout and growth funds from Vitruvian, Thoma Bravo, Summit Partners and Bridgepoint and 20% to co-investments (first: Qlik). Target 13% IRR / 1.7x before tax over 10 years, €100,000 minimum, 2.5%→1.65% management fee, 20% carry on co-investments only, risk 5/7.
Altix Alt.1
Altix Alt.1 is the first fund-of-funds from Amsterdam-based Altix: a Dutch cooperative that closed in March 2024 with €60 million from 150+ private investors (20% above target) and commits to five institutional mid-market private equity funds — Rivean Capital, Gilde Healthcare, Quadrum Capital, Inflexion and Axcel Partners. Target 2.0–2.5x over a 12-year term, 1% management fee, no Altix carry, €100,000 minimum. Closed to new investors.
Altix Alt.2
Alt.2 is an investment fund that provides access to a diversified portfolio of 4 to 8 European Private Equity funds, targeting mid-market companies. The fund emphasizes the mid-market segment, which offers opportunities alongside higher performance variability. Investors gain exposure to over 100 companies through selected funds with a streamlined structure. The portfolio includes funds such as Inflexion, H2 Equity Partners, Egeria, Pollen Street, IceLake, and Forbion.
Altix Alt.3
Alt.3 is an investment fund that provides access to a diversified portfolio of 8-10 European Private Equity funds, targeting mid-market companies. The fund emphasizes the mid-market segment, which offers opportunities alongside higher performance variability. Investors gain exposure to over 100 companies through selected funds with a streamlined structure. The portfolio of predecessor Alt.2 includes funds such as Inflexion, H2 Equity Partners, Egeria, Pollen Street, IceLake, and Forbion.
Altix Alt.4
Alt.4 is the fourth fund-of-funds from Dutch platform Altix, currently open for subscription. It invests in 10 to 12 leading European mid-market private equity funds, together backing more than 120 companies with growth potential. The fund targets a 10% expected net annual return; confirmed portfolio commitments include Axcel VIII, Investindustrial Lower Mid-Market IV and Gilde Healthcare Private Equity V. Predecessor Alt.3 closed in April 2026 with EUR 140 million from 450+ investors.
Explore further
More funds like this
This is an unverified fund profile written by FundScouter and may contain inaccuracies.
Are you affiliated with this fund? Claim this fund to verify and manage your fund profile.